NCT02130882View on ClinicalTrials.gov

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 19, 2014

Primary Completion Date

June 1, 2020

Study Completion Date

December 31, 2023

Conditions
Respiratory System AgentsAnti-Asthmatic AgentsHematologic DiseasesLeukocyte DisordersHypereosinophilia
Interventions
DRUG

benralizumab

An afucosylated humanized antibody to IL-5 receptor alpha

OTHER

Placebo

A sterile solution containing 20 millimolar histidine/histidine-hydrochloride (HCl) 0.25 M trehalose dihydrate, and 0.006% (w/v) polysorbate 20, pH 6.0, in saline

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH